Guest Editors
Prof. Seiji Okada
Email: okadas@kumamoto-u.ac.jp
Affiliation: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 860-8555, Japan
Homepage:
Research Interests: Cancer immunotherapy, hematological malignancy, patient-derived xenograft (PDX), mouse model
Assoc. Prof. Aussara Panya
Email: aussara.pan@cmu.ac.th
Affiliation: Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, 50200, Thailand
Cell Engineering for Cancer Therapy Research Group, Faculty of Science, Chiang Mai University, Chiang Mai, 50200, Thailand
Homepage:
Research Interests: Cancer immunotherapy, synthetic biology (cell engineering), therapeutic peptide development
Summary
Molecular targeting therapy has revolutionized cancer treatment by offering precision strategies that disrupt key pathways driving tumor growth, survival, and metastasis. By focusing on tumor-specific molecules and signaling mechanisms, this approach paves the way for more effective and less toxic therapies.
This special issue delves into the latest advances and future directions in targeted anticancer therapy, highlighting breakthroughs in small-molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, RNA-based therapeutics, cancer vaccines, and cell-based therapies. Contributions will explore innovations aimed at oncogenic drivers, tumor suppressor networks, and the tumor microenvironment.
We place particular emphasis on drug resistance, pharmacokinetics, biomarker-guided treatments, and rational combination strategies. By integrating pharmacological insights with molecular oncology, this issue aims to showcase how cutting-edge research translates into clinically meaningful outcomes.
Submissions discussing novel therapeutic mechanisms, preclinical validations, and clinical trial data are welcome, especially those that bridge the gap between laboratory research and personalized medicine. We invite original research articles, reviews, and perspective pieces that tackle the challenges and opportunities in this dynamic and rapidly evolving field.
Keywords
Small molecule, monoclonal antibodies, cancer vaccines, chimeric antigen receptor (CAR)-T/NK/macrophage therapy, biomarker, cancer precision medicine
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue